^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Ionizing radiation emitter

    Related drugs:
    12d
    A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC (clinicaltrials.gov)
    P1/2, N=90, Recruiting, C Ray Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    13d
    A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=22, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    26d
    A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=22, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P1 trial
    1m
    CleavHER: TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. (clinicaltrials.gov)
    P1, N=19, Recruiting, Radboud University Medical Center
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    1m
    A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, C Ray Therapeutics
    New P1/2 trial
    |
    FOLH1 positive
    4ms
    A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=370, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    |
    enzalutamide • abiraterone acetate
    5ms
    A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=370, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    enzalutamide • abiraterone acetate
    6ms
    A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC (clinicaltrials.gov)
    P1/2, N=73, Not yet recruiting, Radiopharm Theranostics, Ltd
    New P1/2 trial
    7ms
    Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting. (PubMed, Sci Rep)
    The fractionated therapy group exhibited significantly lower tumor volumes and did not exceed 200% of the initial tumor volume. 68Ga-labeled sdAbs enabled high-contrast PET imaging and 177Lu-labeled sdAbs, particularly in fractionated regimens, effectively delayed tumor progression and were well tolerated, supporting further clinical translation.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    7ms
    Squaric-acid-engineered FAP2286: A next-generation 68Ga/177Lu theranostic ligand with synergistically enhanced affinity, hydrophilicity, and tumor retention. (PubMed, Bioorg Chem)
    Squaric acid derivatization synergistically elevates affinity, hydrophilicity, and intratumoral residence while preserving safety, establishing 68Ga/177Lu-FAP2286-SA as a clinically translatable, next-generation theranostic pair for FAP-positive malignancies.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    |
    lutetium Lu 177 rofapitide tetraxetan (AAA614)
    7ms
    Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE). (PubMed, Eur J Nucl Med Mol Imaging)
    [89Zr]Zr-girentuximab PET/CT is a sensitive imaging method and offers promise for novel theranostics for mTNBC patients.
    Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)
    8ms
    I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). (clinicaltrials.gov)
    P2, N=120, Completed, Progenics Pharmaceuticals, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    enzalutamide • abiraterone acetate